Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new ...

Study shows ctDNA positivity is the most prognostic factor, demonstrating the potential for Signatera to redefine adjuvant treatment pathways in endometrial cancer This real-world study analyzed 267 ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous ...

Presentations include abstracts from the GALAXY arm of the CIRCULATE-Japan trial, along with new data in Breast Cancer and Squamous Cell Carcinoma of the Head and Neck Natera and its collaborators ...

Largest ever ctDNA study in testicular cancer shows Signatera significantly outperformed standard of care tumor markers Testicular cancer represents approximately 95% of all GCTs1 and is the most ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...

First-of-its-kind study of >1K patients evaluating the impact of adjuvant treatment escalation in patients tested with Signatera™; results to be presented at ASCO GI in Jan. 2025 AUSTIN, ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...